Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY001 in Mesothelin-Positive Advanced Solid Tumors With Peritoneal Metastasis
NCT07909434Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2026
- Primary completion
- Jun 2029
01
Overview
Phase 1, open-label trial of SY001 in solid tumor (2 arms), sponsored by Zhejiang University. Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Maximum Tolerated Dose at 28 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SY001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07909434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909434.